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Background: 2,4-Dinitrophenol (2,4-DNP) is an effective but highly dangerous fat 
burner, not licensed for human consumption. Death cases reported for 2,4-DNP 
overdose, particularly among young adults, have raised concerns about the ineffective 
regulatory control, lack of education and risks associated with impurity, and the unknown 
concentration of 2,4-DNP purchased on the Internet.
Methods: Using a sequential mixed method design and based on a hypothetical scenario 
as if 2,4-DNP was a licensed pharmaceutical drug, first we conducted a qualitative study 
to explore what product attributes people consider when buying a weight-loss aid. 
Focus group interviews with six females and three males (mean age = 21.6 ± 1.8 years) 
were audiorecorded, transcribed verbatim, and subjected to thematic analysis. Sixteen 
attributes were identified for the Best–Worst Scale (BWS) in the quantitative survey with 
106 participants (64% female, mean age = 27.1 ± 11.9 years), focusing on 2,4-DNP. 
Demographics, weight satisfaction, and risk for eating disorder data were collected.
results: In contrast to experienced users such as bodybuilders, our study participants 
approached 2,4-DNP cautiously. Attributes of 2,4-DNP as a hypothetical weight-loss 
drug comprised a range of desirable and avoidable features. Of the 16 selected attri-
butes, BWS suggested that long-term side effects were the most and branding was the 
least important attribute. Effectiveness and short-term side effects were also essential. 
Those in the >25 year group showed least concerns for legality. Neutral BWS scores 
for cost, treatment, degree of lifestyle changes required, and specificity required for the 
hypothetical weight-loss drug to be effective were likely caused by disagreement about 
their importance among the participants, not indifference.
conclusion: With advances in research, 2,4-DNP as a pharmaceutical drug in the future 
for treating neurodegenerative diseases and potentially for weight loss is not inconceiv-
able. Caution is warranted for interpreting the BWS scores. Owing to the difference in 
what data represent at individual vs. population levels, with pooled data, the method 
correctly identifies attributes by which most people are satisfied but misrepresents 
attributes that are individually very important but not universally agreed. Whilst this may 
be an advantage in marketing applications, it limits the utility of BWS as a research tool.
Keywords: diet pill, fat burner, 2,4-dinitrophenol, DnP, weight loss, bodybuilding, eating disorder
FigUre 1 | Chemical structure of 2,4-DNP produced in two forms:  
(a) 2,4-Dinitrophenol and (B) sodium dinitrophenolate. Taken from  
Petróczi et al. (19).
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inTrODUcTiOn
Due to increased concerns of body weight and image, along with 
the widespread use of the Internet and social media platforms, 
the already considerable market of weight-loss drugs and supple-
ments grows rapidly (1, 2). Within this market, various products 
are available which include substances that could pose health 
hazards to users. Like any other market where effective regula-
tory control is lacking (3), the supplement market is also open 
to unethical practice whereby products could contain unlicensed 
ingredients (4, 5) contaminated with controlled substances 
and/or deliberately spiked with potent controlled substances to 
increase effectiveness [e.g., Ref. (6–12)]. The adulterants in the 
latter being unconventional and dose set to produce the desired 
effect, deliberate dietary supplement fraud poses greater health 
risks than trace contamination from lack of quality control (13). 
In addition, regulatory effort to curb economically motivated 
fraud is further challenged by the readily available cross-border 
retail options on the Internet (14). Drugs that are withdrawn 
before marketing and thus not licensed for human consumption 
such as melanotan II or Cardarine (also known as Endurobol or 
GW-501516) (15–17) and/or reintroduced after being officially 
withdrawn decades ago [e.g., Ref. (18, 19)] remain available on 
the black market and easily obtainable via the Internet.
renaissance of 2,4-DnP
One example of substances not licensed for human consumption 
is 2,4-dinitrophenol (2,4-DNP), which is an effective but highly 
dangerous fat burner. Currently, 2,4-DNP has industrial use but 
it is not licensed for human consumption and its sale as such is 
prohibited around the world. Despite the danger, 2,4-DNP has 
re-emerged within the bodybuilding community and extreme 
dieters, particularly among young adults.
History of 2,4-DNP as a Weight-Loss Drug
The attractiveness of 2,4-DNP arises from the fat-burning effects 
without the need of dietary control (20). 2,4-DNP was used in 
diet pills for obesity treatment between 1933 and 1938 under 
brand names of Dinitriso, Nitromet, Dinitrenal, and Alpha 
Dinitrophenol. Owing to its severe side effects, diet pills contain-
ing 2,4-DNP were withdrawn from the market in 1938 (21, 22). 
Over 100,000 people were prescribed the drug, with claims of 
increasing metabolism by up to 50% at a harmless dose (21, 22). 
However, it was disputed whether the drug was as effective and 
harmless as evidence suggested; alongside DNP’s release to the 
public, warnings of the potential toxicity of the compound were 
issued by the council on Pharmacy and Chemistry (23). In 1938, 
there was enough evidence collected to suggest that DNP had 
potential lethal adverse effects and posed a threat to public health. 
As a result, 2,4-DNP was subsequently banned by the Federal 
Food, Drug, and Cosmetic Act (24). Efforts of regulatory bodies 
to protect the public from harm associated with 2,4-DNP are 
counterbalanced by the ease of access and availability through 
Internet retailers (2, 19), and by a plethora of online discussion 
forums that share experiences among users and readily offer 
guidance and advice on what and how to use to chemically boost 
athletic performance or to achieve the desired appearance (25).
Function
2,4-DNP is an organic compound which is chemically manufac-
tured in two forms (see Figure 1). The product is the result from 
the hydrolysis of 1-chloro-2,4-dinitrobenze (26). The compound 
was initially used to manufacture products such as explosives and 
dyes. It was later discovered that it behaved as a protonophore 
in the human body which allowed the movement of protons 
from the mitochondrial intermembrane space across the inner 
mitochondrial membrane, acting as a strong uncoupler within 
oxidative phosphorylation (27).
The outcome of this process causes the breakdown of 
carbohydrates and fats (21). This allows energy from cellular 
respiration to be released as heat rather than being stored as 
adenosine triphosphate, resulting in reduced fat stores and a rise 
in body temperature (27). This was highly attractive as there was 
no recorded effect on proteins or nitrogen excretion (21). Past 
research has proposed the argument that DNP is ineffective, with 
some evidence suggesting that DNP has little effect on the rate of 
weight loss at a therapeutic dose in comparison to dietary restric-
tion (28). In some cases, DNP at a therapeutic level only increased 
metabolic rate by <15% with an outcome of no weight loss, with 
some patients gaining weight due to increased appetite (29).
Recently, the novel central anti-obesity mechanism of the 
action of 2,4-DNP has been evidenced which offers new avenues 
for targeting obesity with 2,4-DNP and other mitochondrial 
uncoupling agents (30–32). The emerging evidence has suggested 
that mitochondrial uncoupling proteins (UCPs) have key roles 
in neuronal plasticity and resistance to metabolic and oxidative 
stress. UCPs are induced by activities such as caloric restriction 
and exercise. 2,4-DNP recreates a similar pathway to these activi-
ties. The resulting outcome has the potential to protect neurons 
against dysfunction and degeneration. This may lead to a possible 
product containing low doses of 2,4-DNP to improve diseases 
such as Alzheimer’s and Parkinson’s disease. A major concern 
would be to certify that the low dose of 2,4-DNP was therapeutic 
(33). Notably, research in these areas is primarily driven by finding 
new ways of targeting mitochondrial coupling and uncoupling, in 
which 2,4-DNP is used as a proof-of-concept drug rather than 
repurposing 2,4-DNP specifically.
Toxicity
These adverse side effects ranged from short-term nausea, vomit-
ing, and increased pulse rate, to increasingly severe long-term 
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effects such as cataracts, hepatotoxicity, and death (34, 35). The 
issue surrounding DNP is that the adverse side effects may be 
triggered at various doses, whether considered therapeutic or not. 
This is because the tolerance to the drug is different for each indi-
vidual; therefore, doses that may be considered “safe” for some 
may be lethal to others. There has also been evidence of a person’s 
tolerance altering over time, allowing previously tolerated doses 
to become lethal (36).
Access
As 2,4-DNP is currently illegal for human consumption, there is 
concern over those accessing the drug whilst it is unregulated. 
Although manufacturers have the potential to contaminate or 
be inconsistent with the purity of their product, increasing its 
potential to cause harm, research has shown that this is not a 
major concern (19).
Motivation
2,4-DNP is used knowingly and willingly by obese individuals 
(37) and those desiring extreme outcomes, such as achieving 
unnaturally low body fat in bodybuilding (38), compensating 
for overeating among bulimia sufferers (39) or motivated by a 
rapid and effective weight loss and used 2,4-DNP as shortcut 
(19, 40). The drug is often taken in cycles, and information 
regarding dosage and personal programs is readily made avail-
able by bodybuilders for others in the industry to follow (25). 
Although this is concerning, bodybuilders appear to control the 
dose and follow a program to reduce the potential lethal effects 
(19). However, there is increasing concern of usage within vul-
nerable groups such as those with eating disorders or young and 
naïve users who are not fully informed about the drug. People’s 
willingness to take the risk with 2,4-DNP—whilst remaining 
low among the general population—has shown to increase 
considerably if there is a relatively large amount of weight gain 
within a short period of time (40).
Regulatory Efforts
Until recently when 2,4-DNP resurfaced in the gym-going popu-
lation as a potent fat burner and more attention has been drawn 
to this substance, thanks to numerous media reports of DNP 
overdose deaths, law enforcement and regulatory bodies were 
largely unaware that protecting the public by controlling sales 
and access in the Internet era is an impossible task (19). Because 
2,4-DNP—and many similar drugs—is easily available on the 
uncontrollable global online drug market, efforts of protecting 
the public are more likely to be effective if preventive and harm-
reduction measures target the potential users, not solely focusing 
on controlling sales and the suppliers.
In fact, having dedicated agencies [FDA in the US, Food 
Standard Agency (FSA) in the UK, EFSA at the EU level] and regu-
latory policies in place means that perceived safety could backfire. 
Consumers of dietary supplements may make their decision in 
a false sense of safety about the products. In fact, research has 
shown that a significant proportion of physically active people rely 
on label information when making decision about supplements 
but only half were concerned about the quality of the informa-
tion (41). It is recognized that providing more information does 
not automatically lead to a greater decision-making autonomy 
or better behavioral choices (42), nor are people sufficiently 
health-literate to be able to make the right decision amidst the 
complexity of evidence for pros and cons (43). Furthermore, pre-
liminary results, with regard to 2,4-dinitrophenol (DNP—used 
as fat burner weight-loss product), suggest that willingness is 
inversely related with the severity of the health consequences 
(40). As such, willingness to take risks with DNP despite health 
warnings appears to be influenced more by the desired goal (the 
magnitude of weight people wished to lose) and having past expe-
rience with similar products than general risk-taking propensity 
or other psychosocial factors.
Due to the market increase via the internet, cases of 2,4-DNP 
misuse are being seen globally in countries such as America, 
England, and China (20, 44). The FSA has had to communicate 
repeatedly to publicly raise awareness about the potentially lethal 
and permanent effects of 2,4-DNP, in an attempt to combat the 
rising health complications and deaths caused by the drug by 
reducing those interested in the drug, alongside warning the 
current users.
Alarmingly, the plethora of personal accounts of successful 
2,4-DNP use in bodybuilding websites, discussion boards, and 
forums (25) gives some the untrue impression that 2,4-DNP is 
suitable for human consumption and may be considered a “safe” 
product if used “properly.” Discounting the idea that 2,4-DNP 
poses danger because it may be disguised within slimming pills, 
research has shown that customers buy the product knowingly 
(19). However, 2,4-DNP poses serious health risks to new or 
naïve users who are not experienced with performance- and 
image-enhancing drugs or conscientious of dosage, and lack of 
knowledge on the extent of potential harmful effects (19). This 
has contributed to an increasing number of mortalities caused 
by 2,4-DNP (5, 37, 39, 44–46). It is also important to note that 
although isolated cases of treatments for 2,4-DNP overdoses have 
been reported with varying degrees of effectiveness [see (47)], 
there is to date no established cure or treatment for a 2,4-DNP 
overdose.
Looking forward, the future of 2,4-DNP as a pharmaceuti-
cal drug is not inconceivable. Although the use of 2,4-DNP is 
controversial, there might be a use for 2,4-DNP for treating 
extremely overweight or morbidly obese individuals in a clini-
cally controlled environment.
The benefits in entertaining such hypothetical case are two-
fold: 2,4-DNP is an effective compound for weight loss and its 
use under a controlled clinical setting would require appropriate 
understanding of the unique toxicity profile of 2,4-DNP and 
training for clinical staff. The latter then would carry over to 
successfully treating accidental overdose and preventing tragic 
deaths. Media reports and medical case studies fail to portray how 
2,4-DNP users feel and think about the drug. With a few excep-
tions [e.g., Ref. (19, 25, 40, 48)], thought processes and ration-
alization of 2,4-DNP use have not been adequately captured. 
Understanding people’s motives for taking risk with 2,4-DNP as 
well as understanding how they negotiate the risks and where 
they draw the line is vital for devising meaningful prevention and 
harm-reduction strategies [see Presentation S1 in Supplementary 
Material for an example of a real-world case study (49)].
TaBle 1 | Focus groups demographics.





substances in the past
Group 1 M1 Male 23 Fitness/sport No
Group 1 F1 Female 20 Appearance Yes
Group 1 F2 Female 21 Appearance Yes
Group 1 F3 Female 25 Appearance No
Group 1 F4 Female 23 Health No
Group 2 M1 Male 21 N/A No
Group 2 M2 Male 21 Fitness/sport No
Group 2 F1 Female 21 Fitness/sport No
Group 2 F2 Female 19 Fitness/sport No
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One concern around the re-emerged 2,4-DNP is that despite 
official warnings and media reports, 2,4-DNP is continuing to 
show activity within the weight-loss community and it seems to 
be increasing in popularity. One plausible approach to mitigate 
risks against the unintended overdose is to produce 2,4-DNP 
as a weight-loss drug again to ensure quality control and safety 
of this—otherwise still dangerous—drug. This controversial 
proposition could be rationalized on the premise that regulat-
ing production and distribution, while still making the drug 
available, could reduce harm from questionable quality and 
uncertainty around concentration. Equally, it can be argued that 
this approach would still be too dangerous, and instead regula-
tory efforts should focus on improving control over the illegal 
supply. Regardless of the route taken for regulation, education 
with harm prevention and reduction in mind is warranted, and 
the more we understand the motives and barriers behind using 
2,4-DNP (and similarly risky substances) the better we can tailor 
health education to the users’ wants, needs, and motives. Often, 
successful health education for prevention and harm reduction 
requires taking a holistic approach and addressing the problem in 
a broader context. In the present study, the key research question 
is not restricted to 2,4-DNP specifically, but rather, 2,4-DNP is 
used as a controversial example.
Thus, using a hypothetical scenario, in this study we set out to 
explore whether producing the drug with proper quality control 
and advice on safe use would (1) increase willingness to use and 
(2) reduce harm from 2,4-DNP and investigated what factors 
people would consider important in buying 2,4-DNP if it would 
be a licensed pharmaceutical drug.
Alongside this, we also investigated whether demographic 
details (age, gender, educational level) and health condition 
(disordered eating) influence the importance of these factors. 
This will give an indication of who may be at a higher risk of 
purchasing unsafe weight-loss substances such as 2,4-DNP.
MaTerials anD MeThODs
Based on the exploratory nature of the research questions, a 
sequential mixed method design (50) was used within the current 
study. Specifically, the research undertook two phases: first, we 
conducted two focus group interviews which served as an elicita-
tion for the survey content, followed by a quantitative survey. 
Focus groups concentrated on the factors young people would 
consider before buying weight-loss supplements and drugs, such 
as 2,4-DNP. The results from the elicitation phase contributed 
toward a self-reported survey which was composed of 31 closed 
questions and investigated what factors would be considered 
most or least important in the possible scenario of 2,4-DNP as a 
licensed weight-loss drug.
ethical considerations
The study was approved by the Research Ethics Committee of 
the Faculty of Science, Computing and Engineering, Kingston 
University, under the delegated approval scheme. Participation 
in the study was voluntary and anonymous. Participants were 
fully informed about the aim of the study and conditions of 
participation. Consent was implied by voluntary participation in 
the focus group and/or by completing and returning the survey. 
Focus group participants also gave written informed consent to 
the use of their demographic information such as age and gender, 
purpose for weight loss and past experience with weight-loss 
products—with anonymity preserved—for scientific purposes 
and academic dissemination. Consent was obtained prior to the 
focus group, and participants were asked to complete the “personal 
information sheet” which contained questions about the above 
demographic details. Participants received no compensation.
Qualitative Phase: Focus group interviews
Participants and Sampling
Following institutional ethical approval, convenience sampling 
was used to recruit (in person) university students between 18 and 
30 years of age via personal networks. The focus groups contained 
six females and three males with a mean age of 21.56 ± 1.71 years. 
In the focus groups, only two participants had previously used 
weight-loss substances both of which were female and with their 
main concern being appearance (see Table 1).
The age distribution in the first focus group was slightly more 
spread (ranging from 20 to 25 years) than in the second group 
(age range of 19–21  years). Both groups were mixed in terms 
of gender and involvement in sport and exercise but only the 
first group included participants with the experience of using a 
weight-loss product.
Process
Participants were given documents providing a brief background 
on the topic (participants’ prior knowledge of 2,4-DNP was not 
assessed in the current study), a consent form, and a personal 
information sheet to gather the demographics of the focus 
groups (i.e., gender, age, purpose for weight loss, and whether 
participants had taken weight-loss substances—see Table  1). 
Participants were informed about the purpose of the study, the 
voluntary nature of participation, and the confidential nature of 
the focus groups. Focus groups lasted between 30 and 45 minutes 
were audiorecorded and transcribed verbatim by the first author.
Focus Groups
Semi-structured focus groups were used to collect information 
on topics surrounding weight-loss drugs and substances in 
terms of possible benefits, negatives, outcomes and specifically 
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the factors considered when buying weight-loss drugs such 
as 2,4-DNP. Based on recommendations within the literature 
(51), each focus group consisted of four to five participants. 
Participants were asked to consider the scenario of 2,4-DNP as 
a possible weight-loss drug and what factors they or others may 
consider before buying the products. The focus group interview 
matrix, alongside the questions, is presented in Presentation S2 
in Supplementary Material.
Data Analysis
Focus group transcripts were analysed using a thematic analysis. 
Following Braun and Clarke’s (52) procedures, transcripts were 
read and re-read to promote content familiarity. Data were then 
analysed via a process of line-by-line coding to allow themes 
(i.e., the factors considered when buying weight-loss drugs such 
as 2,4-DNP) to emerge. Once identified, themes were labelled 
and grouped together to create higher-order themes. Finally, the 
data were revisited to ensure that each theme was appropriately 
represented. Following the second focus group, a satisfactory 
level of saturation regarding important attributes of 2,4-DNP 
was reached.
Quantitative Phase: Questionnaire study
Participants and Recruitment
In line with the qualitative phase, individuals over 18  years of 
age were recruited for the survey phase using convenience and 
snowballing sampling techniques. Apart from the age limit of 
18 and over, no specific inclusion/exclusion criteria were set for 
this phase of the research. The questionnaire was made available 
online using a closed survey platform (SurveyMonkey) and as a 
hard paper copy. The content of the two surveys was identical. 
This allowed participants to be recruited online via social media 
and in person.
Measures
Attributes of 2,4-DNP as a Hypothetical Weight-Loss Drug
Desirable attributes of a 2,4-DNP as a hypothetical weight-loss 
drug were identified using the Best–Worst Scale (BWS) technique 
which involves choice modelling. In this method, multiple options 
are provided in several iterations but only the best and the worst 
option are selected in each case. This method is a multiple-choice 
extension of the paired comparison method, which is scale-free 
and forces participants to make a selective choice among the 
issues under consideration (53). The attractiveness of the method 
in market research is that respondents are forced to trade off the 
most desirable features against the “would-be-nice-to-have” 
attributes, which resembles real-life decision making. For exam-
ple, when having an ethically produced premium quality product 
at a low price is not possible, customers must make a choice of 
which attribute is more important to them (e.g., ethics, quality, 
or price). Similarly, an ideal weight-loss product would be highly 
effective but also pleasant and free of side effects but this may not 
be possible in real life.
In the current study, the BWS was formed around the 16 factors 
produced from the two focus groups (see Table 2). The template 
design was produced within Datagame (a gamification tool for 
online surveys, https://datagame.io/) (54) and was set to produce 
20 unique sets of four of the 16 factors in each question without 
repeats. In the questionnaire, each attribute appears five times. In 
this survey, the BWS was embedded in a hypothetical scenario. The 
scenario provided a brief background of 2,4-DNP and its current 
use in society alongside its potential dangers. The hypothetical 
situation specified that a pharmaceutical company is considering 
reintroducing 2,4-DNP on the weight-loss drug market and want 
to explore what customers think about 2,4-DNP using a market 
survey. Participants are asked to place themselves as a participant 
in this market research and to consider what factors they felt were 
most or least important. The scenario and the full BWS survey are 
presented in Presentation S2 in Supplementary Material.
Eating Behaviour and Disordered Eating
To assess participants’ at risk status for disordered eating, six 
questions from the EAT-26 test [Part C (55)] were used. EAT-26 
is an established screening measure (not a diagnostic tool) to 
determine a possible eating disorder or a person who may be 
at risk. Section C of the test comprises six questions: (1) Gone 
on eating binges where you feel that you may not be able to stop? 
(Defined as eating much more than most people would under the 
same circumstances and feeling that eating is out of control.); (2) 
Ever made yourself sick (vomited) to control your weight or shape? 
(3) Ever used laxatives, diet pills, or diuretics (water pills) to control 
your weight or shape? (4) Exercised more than 60 min a day to lose 
or to control your weight? (5) Lost 20 pounds or more in the past 
6 months? (6) Have you ever been treated for an eating disorder? 
The first four questions were rated as Never/Once a month or 
less/two to three times a month/Once a week/two to six times 
a week/once a day or more whereas the last two questions were 
answered as Yes/No. The EAT-26, both the belief section and the 
behavioural aspects, is one of the most widely used screening 
tools for identifying high-risk individuals for referral to clinical 
evaluation, consistently showing good psychometric properties 
(56, 57). It has been noted that beliefs manifest to a larger extent 
than behavioural symptoms, suggesting that beliefs are the 
precursors for developing disordered eating (58, 59). Those who 
report behavioural symptoms respond to the belief items congru-
ently, but the opposite is not necessarily the case (i.e., beliefs can 
present without behavioural symptoms).
Satisfaction With Weight
Satisfaction with weight was recorded with three progressive 
questions. First, participants were asked if they were happy with 
their current weight (Yes/No) and whether they wanted to lose 
weight (Yes/No). In case the answer was yes to the weight-loss 
goal, the main reason behind this goal was further explored. To 
facilitate statistical analysis, closed question format questions 
with pre-set answers were used (e.g., Appearance/Health/Fitness/
Other, with open text option).
Demographics
Demographic information we collected included age, gender, 
ethnicity, employment status, and highest completed education 
level. The categories within the highest completed education 
level included GCSE, A-Level/B.Tech, Undergraduate level 4, 
Undergraduate level 5, Degree, Postgraduate, and other. Ethnicity 
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categories were based on the categories recommended by the 
Office for National Statistics (60): White, Mixed/multiple ethnic 
groups, Asian/Asian British, Black/African/Caribbean/Black 
British, or other. Finally, employment status was split into five 
categories: unemployed, student, part-time, full-time, or other.
Data Analysis
Following the selection count method [e.g., used in Ref. (61–63)], 
we used simple count data analysis (i.e., the scoring was based on 
how many times an attribute is ranked as “most important” and 
“least important”). Previously, Marley and Louviere (64) showed 
that this simple calculation is a close and suitable approximation 
of the true scale values obtainable from multinomial logit analy-
ses. When an attribute is selected as most important, a score of 
1 was given, and when an attribute is selected as least important, 
a score of −1 is given. To obtain the BWS score for each item 
at the individual level, the difference between “most” and “least” 
rankings was taken, which resulted in a rank between +5 and −5. 
The aggregated BWS scores for the 16 attributes for the sample 
were obtained by calculating the average time that each attribute 
was mentioned. In this scale, a score of +5 indicates a “very 
important” attribute and a score of −5 indicates that the attribute 
is “not important at all.” By coding “least” important as a negative 
value and “most desired” as a positive value allows for calculating 
not only the preference counts but also to calculate the mean [and 
standard deviation (SD)] without the need to note whether the 
counts come from the most or the least preferred choices.
Descriptive data are reported as median, mean and SD, fre-
quencies, and/or percentages. We dichotomised age (18–25 years 
and >25 years) and at-risk status for eating disorder (i.e., having at 
least two affirmative answers of the six screening questions). Two 
affirmative answers were used instead of the traditional “having 
an affirmative answer” because the relative high proportion of 
athletes in the sample might routinely control their weight for sport 
reasons. Comparisons between two groups were tested using a fac-
torial ANOVA. The association between categorical variables was 
tested using chi-squared statistics with Fisher’s exact significance. 
Statistical significance was set at p <  0.05 and tested two-tailed 
unless specified otherwise. Excel version 2016 for windows and IBM 
SPSS Statistics 22 were used for data entry and statistical analysis.
resUlTs
Qualitative Phase: Focus group interviews
Focus group interviews yielded 16 themes which reflected the 
characteristics and factors considered when buying weight-loss 
drugs such as 2,4-DNP. Themes, theme explanations, and sup-
porting evidence are presented in Table 2. The themes on drug 
characteristics were used as attributes for the BWS in the survey.
It is important to note that despite an agreement in relation 
to the importance of drug characteristics, participants did not 
always agree on how important each attribute was or the reasons 
why they felt it was important. For instance, participants agreed 
that the cost of a drug (such as 2,4-DNP) was important but 
some participants felt that a high price point would prevent or 
discourage them from buying it. As one 21-year-old female with 
experience of using weight-loss substances explained: “I think 
the price [of 2,4-DNP] would hinder me, as it would probably cost 
ridiculous amounts of money, I think that would be the point where 
I’d be like no I don’t want it that bad” (Focus Group 1—F2). By 
contrast, other participants felt that the price would not prevent 
them from buying the drug and that they may actually choose a 
more expensive option, if they believed it would be more effective. 
As another 21-year-old female participant stated: “I know myself 
if I went to buy a drug and there was one that cost 50p and one 
that cost £10, I would probably be like the £10 one is more effec-
tive” (Focus Group 2—F1). The following quote captures these 
contracting views surrounding the importance of cost:
You get people that are like if it’s like £30 cheaper then 
its not going to make a huge amount of difference and 
you get people at the other end of the scale who go well 
it’s the most expensive so it must be the best. (Focus 
Group 1—M1)
In addition to cost, participants also differed in their views 
regarding the preferred administration (i.e., formulation) and 
how the drug is taken (i.e., treatment). For instance, some par-
ticipants felt that there was a stigma associated with taking pills 
for weight loss: “I think there’s a lot of stigma around taking pills 
though…like if you’re talking to someone and saying you’re taking 
pills for weight loss…their immediate reaction would be like are 
you sure, where did you get them from, are they legit kind of thing, I 
probably would go for a shake” (Focus Group 1—F2), whilst other 
participants favoured the simplicity and efficiency of pills and 
favoured this over other formulations. The following quote from 
a 19-year-old female illustrates this point:
I don’t like putting things in water, it’s too much effort 
and it tastes horrible so as soon as I can take it in a tablet 
and its just done in a couple of seconds for me that is 
ideal, it would be things like powder and suppository 
that would be a massive no! (Focus Group 2—F2)
Building on this point, although the majority of participants 
preferred taking drugs orally (via pills or shakes), some par-
ticipants felt that injecting drugs were favourable especially if it 
resulted in a reduced dosage. As one participant explained:
I would prefer an injection if it was less often… just 
because I wouldn’t have to remember every day, I would 
be happy to go to my doctor if it was like once a week… 
especially if you can just go to the nurse and like get it 
(Focus Group 2—F1)
Quantitative Phase: Questionnaire
The survey sample consisted of 106 individuals (64% female). The 
mean age of the sample was 27.08 ± 11.92 years with the majority 
(n = 81) being between 18 and 25 years of age. For this reason, 
age groups were divided as 18–25 and over 25. Sixty-five percent 
of the participants were students.
Attributes of 2,4-DNP as a Hypothetical  
Weight-Loss Drug
The relative importance of the 16 attributes for 2,4-DNP as a 
hypothetical weight-loss drug is depicted in Figure 2 (depicting 
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TaBle 2 | Themes, theme explanations, and supporting evidence for the factors considered when buying weight-loss drugs such as 2,4-DNP.
Theme Theme explanation supporting evidence
Accessibility How easy is it to access the drug (e.g., 
online, pharmacy, prescription-only, over  
the counter)
“I think more people would be willing to buy it if it [2,4-DNP] were more readily available  
but I think for the sake of safety that you should buy it over the counter”  
(Focus Group 2—F1)
Effectiveness How well the drug achieves the desired 
results (i.e., weight loss)
“I think if a drug is effective, and they are really good at marketing that, it would beat all the 
other factors, I mean you will always find a way to store it, or find a way to take it if it’s that 
important to you” (Focus Group 2—F1)
Degree of lifestyle change 
required 
The extent to which individuals have to 
change their lifestyle for a drug to be 
effective (i.e., increasing exercise, water 
intake, managing diet) 
“I definitely would want to do a bit of research, does it say it only works with something  
else, like do you have to drink a lot of water every day to make sure it works? Do you  
actually still have to do exercise? Or do you drop the weight by sitting on the sofa still?” 
(Focus Group 2—M2)
Adherence required The period of time in which you have to take 
a drug for and the dose required
“If it’s something like weight loss, it’s gonna be quite a long time before you really notice 
a difference so having to remember to take it every 4–5 h would become a bit of a chore” 
(Focus Group 2—M2)
Dosage How often a drug needs to be taken (e.g., 
once a week/several times a day)
“If it’s like a tablet, I have to take at a specific time of the day, even like several times a day, 
I’m not good at that so it would probably be like, maybe if like it was only effective if you like 
take it exactly at like 5 h intervals, then I would just be like that is never going to happen” 
(Focus Group 2—F1)
Short-term side effects Temporary negative effects (e.g., headaches, 
mild rashes, pain) as a consequence of the 
drug
“If it’s small stuff you could live with like not driving a car, or even a rash as long as it’s not 
painful, people would be more inclined to just do it anyway…whereas if it’s something that 
actively stops you from doing something or causes a lot of pain and discomfort I think  
that’s when people would be like no, it’s not worth it” (Focus Group 2—M2)
Long-term side effects Severe negative effects that become 
permanent/irreversible (e.g., chronic 
migraines, blindness) as a consequence of 
the drug
“I would be on board, if it was very temporary and I would lose weight as a result of it.  
I could use this drug for x amount of time, but I can’t do this, then I’d probably be willing  
to put my life on the side and lose weight, and then find my life again, but side effects  
that I would really would be a no for me, would be if I got really ill, or a danger that  
I become really ill… if I’m going to go blind or something” (Focus Group 2—F1)
Cost The price of the drug “I think the price would hinder me, as it [2,4-DNP] would probably cost ridiculous amounts  
of money. I think that would be at that point where I’d be like no I don’t want it that bad” 
(Focus Group 1—F2)
Formulation The physical state of the drug (e.g., pill, 
liquid, powder form)
“I think there’s a lot of stigma around taking pills…like if you’re talking to someone and  
saying you’re taking pills for weight loss…their immediate reaction would be like are you  
sure, where did you get them from, are they legit kind of thing, I probably would go for a 
shake” (Focus Group 1—F2) 
Specificity If the drug targets a specific/localised area 
of the body or is generalised across the 
whole body
“Everyone has bits of their body where they have more fat than other parts of their body  
and if someone takes it and they start to lose weight like on their bum but not their  
stomach they might not take it anymore so, yeah, it [the drug] needs to target where”  
(Focus Group 2—M2)
Legality Whether the use of a drug is within the law 
or not
“I think young people and athletes are the ones who are gonna buy something illegal… so, 
if someone just wants to lose a few kilos they’re not gonna look into anything illegal, I think 
they’ll just go to the pharmacy” (Focus Group 2—M1)
Reviews and experiences Other people’s opinions and experiences of 
using a weight-loss drug. 
“I have gone on the internet and researched so many things, drug control and stuff like  
that, and going on forums, other people’s experiences versus like science, and stuff like  
that helps, reading peoples experiences online and checking things, and obviously being 
careful and reading a tonne of things rather than just one website” (Focus Group 1—F3)
Branding The extent to which a brand is known or 
recognisable for certain products 
“I think it [branding] is important as not everyone knows a lot about drugs, so you just  
see brands and go “oh I’ve heard of that before” it must be better… I’ll probably buy 
whatever is more familiar even though it’s more expensive” (Focus Group 2—F2)
Interactions with other 
substances
If the drug interacts with and impacts on 
other medications or substances (i.e., stops 
other medication working)
“[You need to consider] other medications…because they can sometimes have like  
negative effects when drugs are combining with other drugs” (Focus Group 2—M2)
Treatment How the drug is taken (e.g., orally, injections, 
suppositories)
“I don’t like putting things in water, it’s too much effort and it tastes horrible so as soon as  
I can take it in a tablet and it’s just done in like a couple of seconds, for me that’s ideal,  
it’d be things like powder or suppository that would be like a massive no”  
(Focus Group 2—F2) 
Storage and preparation How the drug needs to be stored (e.g., in 
the fridge) and prepared (e.g., needs to be 
dissolved)
“I’d probably be less inclined to take it, if it [storage and preparation] was complicated, yeah 
like if there was some sort of complicated process to it” (Focus Group 1—F2)
TaBle 3 | Attribute Best–Worst Scale counts, interval scale difference scores, and (pseudo-)ratio scale.
attributes number of times 
ranked 5× as most 
important
number of times 
ranked 5× as least 
important
number of times 
ranked as most 
important (Mi)
number of times 










Accessibility 0 0 22 119 −97 11 −0.84
Adherence 0 1 132 31 −101 12 0.72
Branding 0 34 8 246 −238 14 −1.71
Cost 1 0 109 61 48 7 0.29
Dosage 1 1 30 180 −150  13 −0.90
Drug Specificity 6 0 60 68 −8  10 −0.06
effectiveness 0 4 252 6 246 2 1.87
Form 3 0 3 355 −352 16 −2.39
Interactions (with medicines) 10 1 143 50 93  5 0.53
Legality 0 0 201 40 161 4 0.81
Lifestyle change 5 0  58  65 −7  9 −0.06
long-term (lT) side effects 0 0 439 2 437 1 2.70
Reviews and experiences 0 0 132 50 82 6 0.49
Short-term (ST) side effects 5 0 226 21 205  3 1.19
storage and preparation 0 17 3 317 −314 15 −2.33
Treatment 0 0 71 37 34  8 0.33
FigUre 2 | Aggregated Best–Worst Scale scores. Dark blue, median score; 
light blue, mean score; error bars represent standard deviation. Attributes on 
the x-axis are (1) long-term side effects, (2) effectiveness, (3) short-term side 
effects, (4) legality, (5) interactions with other substances, (6) reviews and 
experiences of others, (7) cost, (8) treatment, (9) degree of lifestyle change 
required, (10) specificity, (11) accessibility, (12) adherence required, (13) 
dosage, (14) formulation, (15) storage and preparation, and (16) branding.
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the average times an attribute was selected as most and least 
important) and Table 3 (summarising the outcome of the item 
count methods). Stratified analyses of the average times an attrib-
ute was selected as most and least by age group, gender, and at risk 
for disordered eating status are shown in Table 4.
Based on the survey results, the most important attributes for 
such a drug were long-term side effects, followed by effectiveness 
and short-term side effects, with branding, formulation, and 
route of administration (formulation) being the least important. 
Drug interactions, user reviews, cost, treatment, lifestyle changes 
required, drug target specificity, access, and duration of the treat-
ment were placed in the middle region (BWS scores between +1 
and −1).
Table 4 and Figure 3 offer a more detailed analysis of the BWS 
choices. Taken together, the results indicated that across both 
gender age groups, the highest scoring factor was long-term side 
effects (LT side effects) and the lowest scoring factor was branding. 
The female group ages 18–25 also rated short-term side effects as 
important. Both younger age groups and females over 25 selected 
effectiveness as an important factor and storage and preparation 
as unimportant. The older age groups and females between 18 and 
25 years of age ranked form as unimportant. The older age groups 
showed a higher concern in terms of legality, in comparison to 
18–25 males and females. Statistically significant differences 
were only found for age effect on accessibility (p <  0.001) and 
legality (p = 0.029), and gender effect on branding (p = 0.026) 
and formulation (p = 0.002). The latter also showed a significant 
interaction effect between gender and at-risk status (p = 0.035). 
These are marked in Table 4, along with the corresponding test 
statistics.
In stratified analysis by reasons for weight loss, the data 
showed a statistically significant difference in ranking dosage 
and long-term side effects between those who were satisfied with 
weight and those who were not. Those satisfied with body weight 
scored dosage (p = 0.040) and long-term side effects (p = 0.019) 
with a significantly lower rank in comparison to those unsatisfied 
with body weight. Alongside this, there was a significant differ-
ence in long-term side effect ranks between those who want to 
lose weight and those that do not. Those wanting to lose weight 
scored a significantly higher importance (p =  0.003) towards 
long-term side effects than those who do not want to lose weight. 
The data show that those who selected health as the main reason 
for weight loss scored effectiveness differently from those who 
chose appearance (p = 0.014) or fitness (p = 0.012). Those who 
chose health for main reason for weight loss scored effectiveness 
significantly lower than those who chose the appearance or 
fitness. The only significant result within eating behaviour was 
those who were not at risk ranked branding significantly lower 
than those at risk.
TaBle 4 | Ranked means Best–Worst Scale attribute scores within 2,4-DNP scenario by age and gender.






Over 25 years 
male  
(n = 7)
Over 25 years 
female  
(n = 22)
not at risk for 
De male  
(n = 29)
not at risk for 
De female  
(n = 39)
at risk for 
De male  
(n = 9)
at risk for 
De female 
(n = 29)
Accessibility −1.23a −1.20a 0.41a −0.57a −0.32 −0.89 −1.78 −1.00
Adherence −0.90 −1.02 0.0 −1.36 −0.72 −0.89 −0.78 −1.45
Branding −2.90b −3.43b −2.57b −3.91b −2.72 −4.03 −3.22 −3.00
Cost 0.61 0.64 −0.43 −0.09 0.97 0.26 −0.11 0.59
Dosage −1.42 −1.13 −1.0 −1.95 −1.38 −1.56 −1.22 −1.17
Drug Specificity −0.16 −0.33 −0.14 0.62 −0.07 0.14 −0.44 −0.24
Effectiveness 2.45 2.41 2.00 2.25 2.31 2.21 2.56 2.57
Form −1.68 −2.63 −2.14 −2.27 −2.07c −2.44c −0.78c −2.62c
Interactions with other  
substances
0.97 1.07 −0.14 0.82 0.72 1.03 0.88 0.93
Legality 0.68d 1.61d 2.57d 2.18d 1.00 1.97 1.11 1.55
Lifestyle change −0.2 0.22 −1.14 −0.14 −0.50 0.11 0.00 0.10
Long-term (LT) side  
effects
3.68 4.07 4.14 4.59 3.59 4.21 4.33 4.28
Reviews and  
experiences
0.73 0.83 0.14 0.95 0.71 0.87 0.33 0.86
Short-term (ST) side  
effects
2.10 1.73 0.71 2.59 1.86 2.03 1.78 2.00
Storage and preparation −2.74 −2.96 −2.43 −3.45 −2.59 −3.08 −3.00 −3.17
Treatment 0.35 0.43 −0.14 0.18 0.17 0.46 0.56 0.21
Statistical significance (at p < 0.05) is marked.
aMain effect: age [F(1,101) = 13.957, p < 0.001].
bMain effect: gender [F(1,102) = 5.080, p = 0.026].
cMain effect: gender [F(1,102) = 10.267, p = 0.002]; interaction effect: [F(1,102) = 4.580, p = 0.035].
dMain effect: age [F(1,102) = 4.883, p = 0.029].
FigUre 3 | Best–Worst Scale choice counts [n (100%) = 106]. FigUre 4 | An illustrative example of personal preferences for attributes. 
Person A: a 21-year-old male who is happy with his current weight and he 
does not want to lose weight, at risk for disordered eating score is 1/6; 
Person B is an 18-year-old male who is happy with his current weight and he 
does not want to lose weight, at risk for disordered eating score is 0/6; 
Person C is a 20-year-old female, who is not happy with the current weight 
and she wants to lose weight, at risk for disordered eating score is 4/6. Black 
line represents the average BWS score for the group.
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Juxtaposing qualitative and quantitative data, the overall pic-
ture emerges from the detailed analyses suggesting that attributes 
everyone agreed upon as important or as unimportant scored 
accordingly on the BWS scale (close to 5 and close to −5) but 
those attributes where participants in the focus group disagreed 
scored as “neutral” (neither important or unimportant). Using 
three participants from the set of 106, Figure 4 illustrates these 
notable differences at the individual level.
As the black line (representing the sample average) shows, 
the attributes were arranged in the order of importance, going 
from not important (−5) to very important (+5). Overlaying 
individual scores on the sample average highlight the contrast-
ing views on attributes such as cost, change in lifestyle, and 
dosage. By contrast, the patterns of scores are fairly consistent 
across the participants for long-term health effects, effective-
ness, and branding.
FigUre 5 | (a) Satisfaction with current weight. (B) Intention to lose weight in the stratified sample by age, gender, and at risk for developing eating disorder.
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Eating Behaviour
The 18–25 age group showed a higher risk of developing a 
potential eating disorder than those aged over 25 years of age. 
Specifically, within the 18–25 age group, under 10% of males and 
20% of females were classified as being a non-risk. By contrast, 
within the over 25-age group, over 30% were classified as a 
non-risk.
Participants who selected appearance or fitness for the purpose 
of weight loss are at a higher risk of a potential eating disorder 
than those who chose health. These results may show some bias, 
as only a small number (14% of overall response) of participants 
were represented within the health category.
Satisfaction With and Intention to Lose Weight
Satisfaction with weight was significantly associated with gender 
(χ2 = 6.076, p = 0.016) and age (χ2 = 6.114, p = 0.017). Satisfaction 
with current weight and “at-risk” status for developing eating dis-
order only reached the level of statistical significance if one-tailed 
test statistics were considered (χ2 = 3.992, p = 0.067/p = 0.036 
one-tailed).
Intention to lose weight showed statistically significant 
association with gender (χ2  =  9.206, p  =  0.003) but not age 
(χ2 = 1.718, p = 0.252). Similar to the satisfaction with current 
weight, “at-risk” status for developing an eating disorder only 
reached the level of statistical significance for the intention to lose 
weight if one-tailed test statistics were considered (χ2 =  4.402, 
p = 0.053/p = 0.028 one-tailed).
Using a stratified sample (Figure  5), the data indicate a 
significant dissatisfaction in weight from the over 25 age 
groups with 68.2% of females (25+ years) being unhappy with 
current weight and 6 of the 7 males over 25 years felt the same. 
Age played a significant role in weight satisfaction for males 
(χ2 = 8.808, p = 0.003). The 18–25 age groups indicated more 
weight satisfaction in comparison to the over 25 age group. The 
female 18–25 age group still indicated slight dissatisfaction, 
with 58.7% being unhappy with body weight, in contrast to 
74.2% of males aged 18–25 showing satisfaction of weight. In 
terms of losing weight, over 70% of males and females over 25 
along with females between 18 and 25 years of age expressed 
desire. By contrast, only 41.9% of males between 18 and 25 years 
of age wanted to lose weight.
The data showed a substantial difference in weight satisfaction 
in different ethnic groups. Those identified with white ethnic 
group were the most dissatisfied with their weight, with 57% 
being unhappy with their current weight. The mixed/multiple 
ethnic group showed a balanced response with a 50:50 ratio, 
whereas both the black/African/Caribbean/Black British and 
Asian/Asian British groups show less dissatisfaction with weight, 
with 66.7 (Black) and 77.8% (Asian) being satisfied with their 
current weight, respectively.
Stratifying the sample by “at-risk” status for disordered eat-
ing showed only one statistically significant association. Among 
males, at-risk status and weight satisfaction were associated 
(χ2 = 4.508, p = 0.037). Regardless of the at-risk status, 60–65% 
of the females were dissatisfied with their current weight and 
70–75% wanted to lose weight. Over 70% of the at-risk male 
group was satisfied with their weight but 51.5% still wanted to 
lose weight.
FigUre 6 | The main reason for wanting to lose weight in the stratified sample by age, gender, and at risk for developing eating disorder.
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Reason for Weight Loss
Age and at-risk status for developing eating disorder were inde-
pendent of the reasons for weight loss. Gender, however, showed 
statistically significant association with reasons for weight loss 
(χ2 = 8.958, p = 0.031), with appearance dominating the reasons 
for females. Frequency counts in the stratified sample (Figure 6) 
show that the most prevalent reason for weight loss among 
females over 25 is appearance with 80% choosing this option. 
In females between 18 and 25 years of age, the results are more 
varied with appearance coming top (57.1%) followed by fitness 
(28.6%) and then by health (14.3%). In males aged 18–25, the 
most common reason for weight loss was fitness and appearance 
(3/7 both) followed by health (1/7). Males over 25 years of age 
showed a very similar pattern. Overall, women showed a greater 
concern towards appearance than men and men showed a greater 
concern over fitness than women.
Generally, at-risk status for both genders is manifested in 
similar patterns. Not-at-risk females indicated health reasons as 
most important for wanting to lose weight as opposed to those at 
risk who put appearance first. Among males, both “at-risk” and 
“not-at-risk” groups ranked appearance and fitness as equally 
important. There was no significant association between age, 
gender, or at-risk status.
DiscUssiOn
2,4-DNP is present in the Internet black market and increasingly 
gaining attention, not only in the hard core bodybuilding com-
munity but also among the members of the general public. This 
project aimed to look into the factors people may consider before 
buying a weight-loss drug such as 2,4-DNP. In order to give an 
indication of who is more susceptible to buy 2,4-DNP and to 
inform public health policies, we also explored how the impor-
tance of these attributes was influenced by personal factors such 
as age, gender, weight satisfaction, and the desire to lose weight.
The overall results are in line with the previous study using 
a hypothetical scenario with 2,4-DNP (40). Participants in the 
study by Hoxha and Petróczi (40) were comparable in terms of 
age and body consciousness, and the study also evidenced inverse 
relationship between the severity of the health consequences 
(side effects) and willingness to take risks with 2,4-DNP as an 
unlicensed industry chemical. Our study indicated that this 
relationship is not affected by having a seal of approval for human 
consumption or quality-controlled pharmaceutical production, 
or branding. The effect of the drug on the body and lifestyle—
both on the desirable and on the avoidable spectrum—appeared 
to be the most influential factor for considering 2,4-DNP.
Women showed a greater concern towards appearance than 
men but less concern over fitness. This is in line with the exit-
ing literature which indicates that exposure to media images 
depicting a thin-ideal body type relates to body image concerns 
within women (65, 66). This may indicate why females are more 
concerned over body weight in accordance to appearance and 
explain the increasing number of deaths in young females due 
to black market slimming pills. Notably, however, 2,4-DNP users 
are predominantly males (19, 25) which might be due to the fact 
that 2,4-DNP is considered a controversial drug even within 
bodybuilding and among those who otherwise use a wide range 
of performance- and image-enhancing substances (19, 48).
In contrast to females, the male participants showed a greater 
concern towards fitness, especially within the younger 18–25 age 
group. There is increasing research indicating men and boys are 
becoming more concerned with body image and are undergoing 
more peer pressure to become slender and muscular [e.g., (67)]. 
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This may be one reason why 2,4-DNP is prevalent within the 
bodybuilding community (48).
Notably, the approach to manage the risks with 2,4-DNP dif-
fered between the current study and of Hoxha and Petróczi (40), 
and the studies in which the primary focus was on bodybuilders’ 
lived experiences and rationalisations (19, 25, 48). Contrary to the 
general views about risks and unpleasant side effects expressed in 
the present study was avoidance (i.e., not doing it if ….), body-
builders’ approach to 2,4-DNP-related risks was to have control 
over as many aspects as possible (19, 48). One plausible reason for 
the observed differences is the use of a situation, which does not 
translate directly to nor can be interpreted as actual behaviour. 
The other, more likely, reason is the qualitative difference in the 
target population. Bodybuilders approached 2,4-DNP from the 
position that using drugs to achieve the desired body shape is 
normal but 2,4-DNP is one extreme measure whereas members 
of the general public showed a conservative approach to using 
drugs in the first place.
Interestingly, having in-depth knowledge and understanding 
of the drug, which was pertinent in all bodybuilding-focused 
studies (19, 25, 48) did not feature among the attributes of 
2,4-DNP as a hypothetical pharmaceutical drug although some 
reference was made to the mode of action in the focus groups.
attributes
The most common factors considered before buying weight-loss 
products were accessibility, reviews, experiences, adherence 
(course), treatment, short-term side effects, long-term side 
effects, effectiveness, storage, preparation, dosage, change in 
lifestyle, cost, interactions with other substances, drug specificity, 
legality, branding, and form of drug.
The highest and lowest ranking factors across the different 
age and gender groups were long-term side effects and branding. 
The long-term side effects were expected to receive a high mark 
of importance as people tend to avoid harm especially with the 
severity and length of effects being unknown. Both young (male 
and female) age groups and females over 25 years of age selected 
effectiveness as a very important factor, indicating that these 
groups may have a higher interest with weight loss.
The older age groups showed a higher concern in terms of legality 
in comparison to those who are younger. These findings suggest that 
younger people may be more willing to take risks to achieve their 
desired physique and as a result are more likely to buy illegal weight-
loss drugs. This may go some way to explaining why the majority of 
mortalities due to 2,4-DNP are among young people (44).
Those wanting to lose weight scored significantly higher in 
terms of importance regarding long-term side effects than those 
who did not want to lose weight. Interestingly, this potentially 
contradicts other research as it may be assumed that those want-
ing to lose weight would have greater-risk willingness, so would 
see a reduced concern towards potential hazards. However, this 
potentially could be because those who wanted to lose weight 
related more to DNP scenarios, than to those who did not want 
to lose weight and may have given a more realistic consideration 
to the potential harms of weight-loss drugs.
Those who chose health as the main reason for weight loss 
scored effectiveness significantly lower. This might be because 
losing a significant amount of weight in a short period can be 
considered unhealthy. Therefore, those who are health conscious 
wouldn’t be as concerned with how effective the drug was. Also, 
it may be assumed that those choosing health over appearance 
and fitness are less likely to purchase a weight-loss product due 
to the potential hazards and so wouldn’t consider effectiveness as 
important as side effects.
Judging from the quantitative BWS scoring alone, it would 
appear that some attributes (e.g., cost, treatment, degree of 
lifestyle changes required, and specificity of the hypothetical 
weight-loss drug) are neither important nor unimportant when 
in fact any one of these factors alone would stop a person taking 
2,4-DNP. The rationale for using BWS instead of scaled responses 
was to capture the relative importance of attributes if a risky 
substance such as 2,4-DNP would be manufactured and sold 
as a pharmaceutical product, and indirectly to shed the light on 
what aspects are the most important to potential consumers of 
2,4-DNP. The latter would help to address public health concerns 
about 2,4-DNP and devise effective preventive and/or harm-
reduction strategies.
Best–Worst Scale method (also known as maximum dif-
ference scaling) originates from consumer research exploring 
relative preferences. The BWS model is a multichoice extension 
of the scale-free paired comparison where respondents are not 
asked to assess the absolute importance of an issue on some 
arbitrary scale but presented as a trade-off choice (i.e., would 
you rather have option A or option B). Because of this charac-
teristic, BWS is thought to resemble the actual cognitive process 
by which consumers make product choices (68). In subsequent 
applications, outside marketing showed that the BWS method 
adequately captures abstract values and value systems (61, 69–71) 
and is suitable to assess a wide range of issues such as health care 
(72, 73), education (74, 75), and sport (71, 76).
Since its conception more than 25 years ago, limitations of a 
direct preference assessment with BWS have started to emerge 
[e.g., 77, 78], showing a clear discrepancy between consumers’ 
declared relative importance of an attribute such as packaging or 
calorie information and the attributes’ actual influence on pur-
chasing. This limitation, however, is not linked to the BWS but 
rather caused by the discrepancy between declared preferences 
and behaviour, the latter being influences by a host of other—
temporary—factors. The issue our results highlighted is different 
and likely caused by the information process between individual vs. 
aggregated levels. BWS is thought to model the thought process 
of a single individual; thus, BWS score is reflective of what this 
person explicitly expresses for preference. When the data are 
aggregated across the sample to represent the population, indi-
vidual differences are lost in the process because extreme polar 
views on the same attribute cancel each other out. The result of 
this process is a strong agreement about attributes that all indi-
viduals believe are important and attributes that are considered 
less important. Attributes that are in fact critically important 
but without agreement in how these attributes should manifest 
(e.g., formulation and route of administration of a drug in our 
study, or the level of lifestyle changes required to make the drug 
work) falsely manifest as neither important nor unimportant. 
From the practical point of view, BWS results could be quite 
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useful for marketing purposes because it makes sense to provide 
features in a product that all individuals deem important and 
avoid those that are considered less important. However, this is 
a serious limitation for applying BWS as a research tool because 
the richness of the data is lost in translation from the individuals 
to the group. Similar caution has been made by Krucien et al. 
(79) finding that, in comparison with the discrete choice experi-
ment (DCE) method, BWS method yields lower quality data for 
developing Health Utility Indices. Based on a systematic review, 
Whitty and Oliveira Gonçalves (80) suggest that profile-case 
BWS and DCE are equally robust measures but they might tap 
into different constructs. Multiprofile BWS might be concord-
ant with DCE outcomes but this observation was based on a 
single study, thus requiring further verification. Unfortunately, 
these observations are not directly applicable to our present 
study because we used object-case BWS (81, 82). Object-case 
BWS, while successfully addressing some concerns associated 
with rating scales having ties (i.e., everything very important 
and socially desirable responding), BWS lacks accuracy and 
discriminatory power to compare respondents with differing 
preferences (81, 82). Furthermore, it must be noted that BWS 
scores alone do not offer any insight into how important the 
entire choice scenario to the respondent and how important 
each attribute is (81, 82). The combination of our quantitative 
and qualitative results offers support to this observation. In our 
study, we partially addressed the first aspect by including and 
analysing BWS in the context of weight satisfaction, weight-loss 
goals, and disordered eating. To address the latter aspect, an 
additional ranking scale is required prompting respondents to 
not only rank attributes in a forced choice setting but also evalu-
ate the importance of each of them. Including this additional 
information could address the issue we highlighted, namely the 
misrepresentation of some attributes as “neutral” by includ-
ing weighting to each attribute. Future studies using BWS for 
research are also recommended to incorporate methods that 
afford individual-level analyses. Triangulating the individual 
and aggregated BWS results with qualitative and/or behavioural 
data could provide useful insights into the method and facilitate 
further development.
limitations
The questionnaire consisted of 31 questions, with some sections 
such as the DNP scenario and BWS containing a considerable 
amount of information resulting in a lengthy survey. It was men-
tioned by a few participants that the survey was too long, with at 
least 26 participants taking over 10 min to complete the survey. 
This may have led to some questions being answered superficially, 
reducing the accuracy of the results.
The majority of participants were young females which 
inadvertently led to females aged between 18 and 25 years to be 
over-represented within the data. Given that females are more 
conscious about weight, talk more about weights (83), and more 
likely to use weight-management clinics and weight-loss products 
(84), this characteristic of the sample may not be a limitation but 
a true reflection of the weight-loss product market.
Lastly, the eating behaviour scale showed some discrepan-
cies, as the tool defines a person at risk of an eating disorder 
with a score of 1 or higher. However, the survey collected 
information from a high proportion of young people, mainly 
students. In this population, many are highly active within sport 
and require high levels of exercise to control weight and remain 
competitive. Therefore, many athletes scored at least a 1 due 
to controlling their weight by exercise. Alongside these, many 
athletes may experience eating binges more frequently due to 
this high activity, in which their body needs to quickly replace 
depleted energy stores.
cOnclUsiOn
Due to the range of side effects, which vary in severity depending 
on a person’s tolerance, 2,4-DNP has remained illegal for human 
consumption since its ban by the FDA in 1938. Facilitated by easy 
access to the substance via the Internet, legislation cannot curb 
its use by the general public which raises public health concerns. 
Despite numerous warnings to make the public aware of the 
dangers from using 2,4-DNP, the drug is still showing activity 
within the weight-loss community.
With advance in research, 2,4-DNP as a licensed pharmaceu-
tical drug in the future for treating neurodegenerative diseases 
with chronic micro-dosing and potentially for aiding weight 
loss is not inconceivable. However, owing to the media reports 
of deaths and irresponsible marketing, supply, and use, 2,4-DNP 
has a reputation of being very risky and rightly so. Participants 
in this study exhibited a reassuringly cautious and conserva-
tive approach to a risky drug like 2,4-DNP. Focusing on young 
adults, we showed that those most interested in weight loss are 
females predominantly 18–25 years of age and indicated that 
both males and females under 25 years exhibited a higher risk 
for disordered eating. Due to the rising body pressure effects on 
these age groups and with a reduced concern towards legality, 
this group of young people are at risk of becoming susceptible 
to different weight-loss products, including 2,4-DNP. Vast 
differences in social group norms (e.g., bodybuilders, athletes) 
around using pharmaceutical aids to weight loss were noted. 
There is little doubt that the market for such products exists and 
current control policies are inadequate; thus there is a need for 
finding new ways for prevention and harm reduction. Failing 
to control the risk through supply and access, public health 
policies should consider pragmatic solutions for controlling 
2,4-DNP-related harm via education as well as research into 
the possibility of making 2,4-DNP a safer drug by controlling 
purity and quality as well as efforts to mitigate against side 
effects.
However, our results expand beyond 2,4-DNP and speak 
for young adults’ approach to using pharmaceutical products 
for achieving a “desired” body, which provide useful insights for 
public health policies. Caution is warranted for interpreting the 
BWS scores. Our combined qualitative and quantitative results 
showed that the BWS method is capable of correctly identifying 
attributes most people feel the same way but misrepresents attrib-
utes that are individually very important but not agreed upon as 
unimportant or insignificant. This feature of the BWS method 
is very suitable for marketing purposes but outcomes should be 
interpreted cautiously in research applications.
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